Current stock value

Last updated on Jul 24, 2014 3:54 PM ET

NASDAQ : SPHS 2.43   
- 0.10

Fact Sheet

PDF Download the Sophiris Fact Sheet

Investor Presentation

PDF Download the Sophiris Investor Presentation


Sophiris Bio Inc. (NASDAQ: SPHS) is a biopharmaceutical company developing a clinical-stage, targeted treatment for the symptoms of benign prostatic hyperplasia (BPH or enlarged prostate), which it believes is an unsatisfied market with significant market potential. Sophiris’ lead candidate for BPH, PRX302, is designed to be as efficacious as pharmaceuticals, less invasive than the surgical interventions, and without the sexual side effects seen with existing treatments. Sophiris is currently enrolling patients in the PLUS 1 Phase III clinical study using PRX302 for the treatment of symptoms of BPH.

View all »   RSSRecent Releases

May 22, 2014
Sophiris Bio to Present at the Jefferies 2014 Global Healthcare Conference

May 19, 2014
Sophiris Enters into Common Stock Purchase Agreement with Aspire Capital to Support Proof of Concept Study of PRX302 in Prostate Cancer